59–006 

114TH CONGRESS REPORT " ! HOUSE OF REPRESENTATIVES 2d Session 114–560 

EXAMINING OPIOID TREATMENT INFRASTRUCTURE ACT 

OF 2016 

MAY 10, 2016.—Committed to the Committee of the Whole House on the State of 

the Union and ordered to be printed 

Mr. UPTON, from the Committee on Energy and Commerce, 

submitted the following 

R E P O R T 

[To accompany H.R. 4982] 

[Including cost estimate of the Congressional Budget Office] 

The Committee on Energy and Commerce, to whom was referred 

the bill (H.R. 4982) to direct the Comptroller General of the United 

States to evaluate and report on the in-patient and outpatient 

treatment capacity, availability, and needs of the United States, 

having considered the same, report favorably thereon with an 

amendment and recommend that the bill as amended do pass. 

CONTENTS 

Page 

Purpose and Summary ............................................................................................ 2 

Background and Need for Legislation .................................................................... 2 

Hearings ................................................................................................................... 2 

Committee Consideration ........................................................................................ 2 

Committee Votes ...................................................................................................... 3 

Committee Oversight Findings ............................................................................... 3 

Statement of General Performance Goals and Objectives .................................... 3 

New Budget Authority, Entitlement Authority, and Tax Expenditures ............. 3 

Earmark, Limited Tax Benefits, and Limited Tariff Benefits ............................. 3 

Committee Cost Estimate ....................................................................................... 3 

Congressional Budget Office Estimate ................................................................... 3 

Federal Mandates Statement ................................................................................. 4 

Duplication of Federal Programs ............................................................................ 4 

Disclosure of Directed Rule Makings ..................................................................... 4 

Advisory Committee Statement .............................................................................. 4 

Applicability to Legislative Branch ........................................................................ 5 

Section-by-Section Analysis of the Legislation ...................................................... 5 

Changes in Existing Law Made by the Bill, as Reported ..................................... 5 

The amendment is as follows: 

Strike all after the enacting clause and insert the following: 


emcdonald on DSK67QTVN1PROD with HEARING
2 

SECTION 1. SHORT TITLE. 

This Act may be cited as the ‘‘Examining Opioid Treatment Infrastructure Act of 

2016’’. 

SEC. 2. STUDY ON TREATMENT INFRASTRUCTURE. 

Not later than 24 months after the date of enactment of this Act, the Comptroller 

General of the United States shall initiate an evaluation, and submit to Congress 

a report, of the inpatient and outpatient treatment capacity, availability, and needs 

of the United States, which shall include, to the extent data are available— 

(1) the capacity of acute residential or inpatient detoxification programs; 

(2) the capacity of inpatient clinical stabilization programs, transitional residential support services, and residential rehabilitation programs; 

(3) the capacity of demographic specific residential or inpatient treatment programs, such as those designed for pregnant women or adolescents; 

(4) geographical differences of the availability of residential and outpatient 

treatment and recovery options for substance use disorders across the continuum of care; 

(5) the availability of residential and outpatient treatment programs that 

offer treatment options based on reliable scientific evidence of efficacy for the 

treatment of substance use disorders, including the use of Food and Drug Administration-approved medicines and evidence-based nonpharmacological therapies; 

(6) the number of patients in residential and specialty outpatient treatment 

services for substance use disorders; 

(7) an assessment of the need for residential and outpatient treatment for 

substance use disorders across the continuum of care; 

(8) the availability of residential and outpatient treatment programs to American Indians and Alaska Natives through an Indian health program (as defined 

by section 4 of the Indian Health Care Improvement Act (25 U.S.C. 1603)); and 

(9) the barriers (including technological barriers) at the Federal, State, and 

local levels to real-time reporting of de-identified information on drug overdoses 

and ways to overcome such barriers. 

PURPOSE AND SUMMARY

H.R. 4982, the ‘‘Examining Opioid Treatment Infrastructure Act 

of 2016’’ was introduced by Rep. Foster (D–IL) on April 18, 2016. 

The bill directs the Government Accountability Office (GAO) to 

evaluate and report on the in-patient and outpatient treatment capacity, availability, and needs of the United States. 

BACKGROUND AND NEED FOR LEGISLATION

Opiate-related overdoses have become a significant cause of injury related to death nationwide. This bill directs GAO to issue a 

report that will provide important information related to treatment 

capacity, availability, and needs throughout the United States. 

HEARINGS

The Committee on Energy and Commerce has not held hearings 

on the legislation. 

COMMITTEE CONSIDERATION

On April 20, 2016, the Subcommittee on Health met in open 

markup session and forwarded a discussion draft entitled the ‘‘Examining Opioid Treatment Infrastructure Act of 2016’’ to the full 

Committee, without amendment, by a voice vote. The discussion 

draft was identical to H.R. 4982. On April 26, 27, and 28, 2016, the 

full Committee on Energy and Commerce met in open markup session and ordered H.R. 4982 reported to the House, as amended, by 

a voice vote. 


emcdonald on DSK67QTVN1PROD with HEARING
3 

COMMITTEE VOTES

Clause 3(b) of rule XIII of the rules of the House of Representatives requires the Committee to list the record votes on the motion 

to report legislation and amendments thereto. There were no 

record votes taken in connection with ordering H.R. 4982 reported. 

COMMITTEE OVERSIGHT FINDINGS

Pursuant to clause 3(c)(1) of Rule XIII of the Rules of the House 

of Representatives, the Committee did not hold a hearing on this 

legislation. 

STATEMENT OF GENERAL PERFORMANCE GOALS AND OBJECTIVES

The goal of the legislation is to examine in-patient and outpatient opioid treatment capacities. 

NEW BUDGET AUTHORITY, ENTITLEMENT AUTHORITY, AND TAX

EXPENDITURES

In compliance with clause 3(c)(2) of rule XIII of the Rules of the 

House of Representatives, the Committee finds that H.R. 4982 

would result in no new or increased budget authority, entitlement 

authority, or tax expenditures or revenues. 

EARMARK, LIMITED TAX BENEFITS, AND LIMITED TARIFF BENEFITS

In compliance with clause 9(e), 9(f), and 9(g) of rule XXI of the 

Rules of the House of Representatives, the Committee finds that 

H.R. 4982 contains no earmarks, limited tax benefits, or limited 

tariff benefits. 

COMMITTEE COST ESTIMATE

The Committee adopts as its own the cost estimate prepared by 

the Director of the Congressional Budget Office pursuant to section 

402 of the Congressional Budget Act of 1974. 

CONGRESSIONAL BUDGET OFFICE ESTIMATE

Pursuant to clause 3(c)(3) of rule XIII of the Rules of the House 

of Representatives, the following is the cost estimate provided by 

the Congressional Budget Office pursuant to section 402 of the 

Congressional Budget Act of 1974: 

U.S. CONGRESS, 

CONGRESSIONAL BUDGET OFFICE, 

Washington, DC, May 9, 2016. 

Hon. FRED UPTON, 

Chairman, Committee on Energy and Commerce, 

House of Representatives, Washington, DC. 

DEAR MR. CHAIRMAN: The Congressional Budget Office has prepared the enclosed cost estimate for H.R. 4982, the Examining 

Opioid Treatment Infrastructure Act of 2016. 

If you wish further details on this estimate, we will be pleased 

to provide them. The CBO staff contact is Zoe ̈ Williams. 

Sincerely, 

KEITH HALL. 

Enclosure. 


emcdonald on DSK67QTVN1PROD with HEARING
4 

H.R. 4982—Examining Opioid Treatment Infrastructure Act of 2016 

H.R. 4982 would direct the Government Accountability Office 

(GAO) to conduct an evaluation of the infrastructure for treating 

opioid and other substance abuse in the United States. The bill 

would require GAO to submit a report to the Congress on the evaluation no later than 24 months after the date of enactment. 

The evaluation would assess the capacity of detoxification and 

stabilization programs, transitional residential support services, 

residential rehabilitation programs, and demographic-specific treatment programs. The evaluation also would measure any geographical differences in the treatment infrastructure and the need 

for residential and outpatient treatment for substance use disorders. GAO’s report would include an assessment of the availability of certain treatment programs and detail any barriers to 

real-time reporting of information on drug overdoses. 

CBO estimates that implementing H.R. 4982 would cost less 

than $500,000 over the 2017–2021 period; any such spending would 

be subject to the availability of appropriated funds. Pay-as-you-go 

procedures do not apply to this legislation because it would not affect direct spending or revenues. 

CBO estimates that enacting H.R. 4982 would not increase direct 

spending or on-budget deficits in any of the four consecutive 10- 

year periods beginning in 2027. 

H.R. 4982 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act and would 

impose no costs on state, local, or tribal governments. 

The CBO staff contact for this estimate is Zoe ̈ Williams. The estimate was approved by Holly Harvey, Deputy Assistant Director for 

Budget Analysis. 

FEDERAL MANDATES STATEMENT

The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office 

pursuant to section 423 of the Unfunded Mandates Reform Act. 

DUPLICATION OF FEDERAL PROGRAMS

No provision of H.R. 4982 establishes or reauthorizes a program 

of the Federal Government known to be duplicative of another Federal program, a program that was included in any report from the 

Government Accountability Office to Congress pursuant to section 

21 of Public Law 111–139, or a program related to a program identified in the most recent Catalog of Federal Domestic Assistance. 

DISCLOSURE OF DIRECTED RULE MAKINGS

The Committee estimates that enacting H.R. 4982 specifically directs to be completed 0 rule makings within the meaning of 5 

U.S.C. 551. 

ADVISORY COMMITTEE STATEMENT

No advisory committees within the meaning of section 5(b) of the 

Federal Advisory Committee Act were created by this legislation. 


emcdonald on DSK67QTVN1PROD with HEARING
5 

APPLICABILITY TO LEGISLATIVE BRANCH

The Committee finds that the legislation does not relate to the 

terms and conditions of employment or access to public services or 

accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act. 

SECTION-BY-SECTION ANALYSIS OF THE LEGISLATION

Section 1. Short title 

Section 1 states that the legislation may be cited as the ‘‘Examining Opioid Treatment Infrastructure Act of 2016’’ 

Section 2. Study on treatment infrastructure 

Within 24 months of enactment of the legislation, the Comptroller General of the United States shall initiate an evaluation 

and submit to Congress a report on opioid abuse disorder treatment services including: 

(1) the capacity of acute residential or inpatient detoxification 

programs; 

(2) the capacity of inpatient clinical stabilization programs, transitional residential support services, and residential rehabilitation 

programs; 

(3) the capacity of demographic specific residential or inpatient 

treatment programs, such as those designed for pregnant women or 

adolescents; 

(4) geographical differences of the availability of residential and 

outpatient treatment and recovery options for substance use disorders across the continuum of care; 

(5) the availability of residential and outpatient treatment programs that offer treatment options based on reliable scientific evidence of efficacy for the treatment of substance use disorders, including the use of Food and Drug Administration-approved medicines and evidence-based nonpharmacological therapies; 

(6) the number of patients in residential and specialty outpatient 

treatment services for substance use disorders; 

(7) an assessment of the need for residential and outpatient 

treatment for substance use disorders across the continuum of care; 

(8) an examination of the barriers of real time reporting of deidentified information on drug overdoses; and 

(9) an examination of the availability of residential and outpatient treatment programs within the Indian Health Service program. 

CHANGES IN EXISTING LAW MADE BY THE BILL, AS REPORTED

This legislation does not amend any existing Federal statute. 

Æ 


emcdonald on DSK67QTVN1PROD with HEARING